Change in dyspnoea score · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
Lung function: FEV1 mL (change from baseline) · acute exacerbations of chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 · adults and children with acute exacerbation of asthma
1 finding from 1 review
PEF (L/min) · adults and children with acute exacerbation of asthma
2 findings from 1 review
Admission to hospital at initial presentation · adults and children with acute exacerbation of asthma
MgSO4 + SABA showed no clear difference in admission to hospital at initial presentation compared with SABA (low certainty).
1 finding from 1 review
Serious adverse events (During ED/hospital admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Any adverse events (During ED/hospital admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Lung function · adults and children with acute exacerbation of asthma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical severity score ‐ Fischl index (120 minutes) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Admission to hospital at initial presentation · adults and children with acute exacerbation of asthma
It is very uncertain whether mgSO4 changes admission to hospital at initial presentation compared with SABA (very low certainty).
1 finding from 1 review
Serious adverse events (During ED/hospital admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Pulmonary function % predicted PEF (60 minutes) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Clinical severity scores (60 minutes) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Admission to hospital at initial presentation · adults and children with acute exacerbation of asthma
MgSO4 + SABA + ipratropium showed no clear difference in admission at first presentation compared with SABA + ipratropium (moderate certainty).
1 finding from 1 review
Patient readmissions · adults and children with acute exacerbation of asthma
MgSO4 + SABA + ipratropium showed no clear difference in readmission (7 to 30 days) compared with SABA + ipratropium (low certainty).
1 finding from 1 review
Serious adverse events (during admission) · adults and children with acute exacerbation of asthma
1 finding from 1 review
Adverse effects Defined as any adverse event occurring post‐admission · adults and children with acute exacerbation of asthma
1 finding from 1 review
FEV1 % predicted · adults and children with acute exacerbation of asthma
1 finding from 1 review
Hospital admissions · children with acute asthma in the emergency department
MgSO4 may leads to lower hospital admissions compared with placebo (low certainty).
1 finding from 1 review
ED treatment duration (minutes) · children with acute asthma in the emergency department
1 finding from 1 review